Cargando…

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

IMPORTANCE: The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an “equivocal” category (average HER2 copies per tumor cell ≥4-6 with HER2/CEP17 ratio <2.0) to be re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Press, Michael F., Seoane, Jose A., Curtis, Christina, Quinaux, Emmanuel, Guzman, Roberta, Sauter, Guido, Eiermann, Wolfgang, Mackey, John R., Robert, Nicholas, Pienkowski, Tadeusz, Crown, John, Martin, Miguel, Valero, Vicente, Bee, Valerie, Ma, Yanling, Villalobos, Ivonne, Slamon, Dennis J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439848/ https://www.ncbi.nlm.nih.gov/pubmed/30520947 http://dx.doi.org/10.1001/jamaoncol.2018.6012

Ejemplares similares

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
por: Press, Michael F., et al.
Publicado: (2016)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022)

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
por: Gupta, Swati, et al.
Publicado: (2019)

Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases
por: Carretero-Barrio, Irene, et al.
Publicado: (2023)

Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
por: Wang, Bo, et al.
Publicado: (2019)

Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
por: Nagarjun, B. R., et al.
Publicado: (2022)

Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre
por: Panigrahi, Manoj Kumar, et al.
Publicado: (2017)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

ASCO 2018: highlights in HER2-positive metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
por: Kim, Gilhyang, et al.
Publicado: (2016)

Update on HER2-directed therapy
por: Slamon, D
Publicado: (2005)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
por: Marchiò, Caterina, et al.
Publicado: (2018)

Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
por: Landgraf, Ralf
Publicado: (2007)

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
por: Liu, Yuanyuan, et al.
Publicado: (2019)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
por: Olayioye, Monilola A
Publicado: (2001)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
por: Schillaci, Roxana, et al.
Publicado: (2012)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
por: Marotta, Michael, et al.
Publicado: (2017)

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
por: Torres-Jiménez, Javier, et al.
Publicado: (2022)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
por: Ji, Hongfei, et al.
Publicado: (2015)

Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases
por: Ayad, E., et al.
Publicado: (2014)

Clinical evaluation of BCL-2/X(L) levels pre- and post- HER2-targeted therapy
por: Zoeller, Jason J., et al.
Publicado: (2021)

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
por: Elster, Naomi, et al.
Publicado: (2018)

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification
por: Ercolani, Cristiana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_60m3mliaa31rk1v6tbmar0tqmu